Merck to acquire Terns Pharmaceuticals for $6.7B to bolster oncology pipeline
Merck (NYSE:MRK), known as MSD outside the U.S. and Canada, has entered into a definitive agreement to acquire clinical-stage oncology firm Terns Pharmaceuticals (NASDAQ:TERN) for approximately $6.7 billion in equity value.










